Fish oil capsules may help hair growth by improving blood flow, but should be used alongside minoxidil for better results. Trusting unverified claims is discouraged.
High-dose Lysine and Histidine supplements caused curly/kinky hair and shedding due to Elastin dysfunction. Minoxidil, white tea, and dark grape juice were mentioned as treatments to inhibit Elastase and mimic Lysyl Oxidase.
The user has been using finasteride for 30 years and recently added colostrum to their routine, noticing darker hair regrowth. They experienced shedding with minoxidil and advise against its use, while highlighting the benefits and side effects of long-term finasteride use.
Minoxidil increases hair count despite high prolactin being linked to hair loss. Blocking DHT is effective, but not always necessary; HMI-115 is a promising treatment for androgenetic alopecia.
Saw palmetto's fatty acids, particularly lauric and linoleic acids, inhibit enzymes linked to hair loss, while sterols like beta-sitosterol are less effective due to poor absorption. The conversation questions which specific compounds in saw palmetto contribute to its anti-androgenic effects.
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.
Investing in pharmaceutical products to treat hair loss and the potential risks associated with that, as well as other treatments such as Minoxidil, Finasteride, RU58841, and a COVID-19 booster.
Hair loss discussion includes LLLT treatments and a satirical condition called PLLLTS, causing patients to resemble lighthouses and attract moths. Some users express concern about others taking the satire seriously.
The conversation discusses the potential benefits and risks of participating in the PP405 hair loss trials, emphasizing that those using Minoxidil or finasteride are less likely to be accepted. Participants are interested in the trial as it offers hope for effective treatment without the side effects associated with current medications.
The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.
The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.
The user tried various hair loss treatments, including Maxogen-X, Dualgen15, minoxidil, finasteride, and dermarolling, but experienced limited regrowth and some side effects. They eventually switched to oral minoxidil, hoping for better results.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
Winlevi (clascoterone), a DHT blocker, is being considered for hair loss treatment, though it's primarily an acne medication. Users discuss its potential effectiveness and note it may only work for a short time.
Combining therapies like scyllo-inositol, alpha-ketoglutarate, and autophagy-inducing supplements may enhance hair growth and prevent hair loss. Reporting individual results can accelerate progress in hair loss treatments.
The user had a hair transplant and is using oral minoxidil and finasteride but seeks advice for treating the crown area. They are looking for additional recommendations for non-transplanted areas.
The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
Magnesium L-Threonate may help treat balding by reducing DKK-1 expression without affecting DHT. Users discuss its potential effectiveness and application methods, with some considering trying it topically.
The conversation discusses the use of pyrrolidinyl diaminopyrmidine oxide (triaminodil) compared to minoxidil for hair loss treatment. The user is considering switching from 5% minoxidil to a product containing 5% triaminodil.
Copper peptide topical is being discussed for hair health, with some users noting it may improve hair volume. There is uncertainty about its effectiveness against hair loss.
The user shared their 4-year hair regrowth progress using finasteride, minoxidil, estradiol, and spironolactone. They noted significant regrowth by the second year and additional benefits from estradiol and spironolactone.
Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.
The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.
The conversation is about creating a DIY topical finasteride solution using ethyl alcohol and propylene glycol. A user suggests using a compounding pharmacy instead.
The user is considering making a homemade topical finasteride solution using an ethanol-based carrier. They are inquiring if a solution containing partially denatured ethyl alcohol and benzalkonium chloride is suitable.
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.